Sujit Basu

Dr. Sujit Basu

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
CSChandrani Sarkar
Chandrani Sarkar
BBBiswarup Basu
Biswarup Basu
DCDebanjan Chakroborty
Debanjan Chakroborty
PDPartha Sarthi Dasgupta
Partha Sarthi Dasgupta
SBSujit Basu
Sujit Basu

30 April 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DCDebanjan Chakroborty
Debanjan Chakroborty
CSChandrani Sarkar
Chandrani Sarkar
BBBiswarup Basu
Biswarup Basu
PDPartha Sarathi Dasgupta
Partha Sarathi Dasgupta
SBSujit Basu
Sujit Basu
Among the regulators of angiogenesis, catecholamine neurotransmitters are of recent interest because of their opposite roles in the regulation of tumor neovascularization. Norepinephrine and epinephrine by acting through specific adrenoceptors increase the synthesis of proangiogenic factors, and thereby, promote tumor growth. In contrast, dopamine acting via its specific D2 receptors inhibits tumor growth by suppressing the actions of vascular permeability factor/vascular endothelial growth factor-A on both tumor endothelial and bone marrow-derived endothelial progenitor cells. These reports identify novel endogenous regulators of tumor angiogenesis and also indicate a new and an inexpensive class of antiangiogenic drugs for the treatment of cancer. [Cancer Res 2009;69(9):3727–30]

5 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DCDebanjan Chakroborty
Debanjan Chakroborty
CSChandrani Sarkar
Chandrani Sarkar
HYHongmei Yu
Hongmei Yu
JWJiang Wang
Jiang Wang
ZLZhongfa Liu
Zhongfa Liu
SBSujit Basu
Sujit Basu
Impaired blood flow in the tumor vascular bed caused by structurally and functionally abnormal blood vessels not only hinders the delivery of chemotherapeutic agents but also aggravates tumor hypoxia, making the tumor cells further resistant to antineoplastic drugs. Therefore, normalization of tumor blood vessels may be an important approach to increase therapeutic efficacy in the treatment of cancer patients. As blood vessels are supplied by sympathetic nerves containing dopamine (DA), and DA regulates functions of normal blood vessels through its receptors present in these vessels, we investigated the effect of DA on tumor vasculature. Here we report loss of sympathetic innervation and endogenous DA in abnormal and immature tumor blood vessels in malignant colon and prostate tumor tissues. In contrast, exogenous administration of DA normalizes the morphology and improves the functions of these vessels by acting on pericytes and endothelial cells, the two major cellular components of blood vessels. DA acts through its D 2 receptors present in these cells to up-regulate directly the expression of angiopoietin 1 (Ang1) in pericytes and the expression of the zinc finger transcriptional factor, Krüppel-like factor-2 (KLF2) in tumor endothelial cells. Importantly, this vessel stabilization by DA also significantly increases the concentration of anticancer drug in tumor tissues. These results show a relationship between vascular stabilization and a neurotransmitter and indicate that DA or its D 2 receptor-specific agonists can be an option for the treatment of cancer and disorders in which normalization of blood vessels may have therapeutic benefits.

11 August 2012 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
CSChandrani Sarkar
Chandrani Sarkar
DCDebanjan Chakroborty
Debanjan Chakroborty
SBSujit Basu
Sujit Basu

6 May 2016 in Angiogenesis
Verified
Journal Article
Closed access
PDF file
KLKai Lu
Kai Lu
MBMadhavi Bhat
Madhavi Bhat
SBSujit Basu
Sujit Basu

24 August 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKai Lu
Kai Lu
DCDebanjan Chakroborty
Debanjan Chakroborty
CSChandrani Sarkar
Chandrani Sarkar
TLTingting Lu
Tingting Lu
ZXZhiliang Xie
Zhiliang Xie
SBSujit Basu
Sujit Basu
Triphala churna (THL) is a combination of three fruits that has been used for many years in India for the treatment of various diseases. There are now reports which indicate that THL can inhibit growth of malignant tumors in animals. However, the mechanisms by which THL mediates its anti-tumor actions are still being explored. Because vascular endothelial growth factor-A (VEGF) induced angiogenesis plays a critical role in the pathogenesis of cancer, we therefore investigated whether tumor inhibitory effects of THL or its active constituents are through suppression of VEGF actions. We herein report that THL and chebulinic (CI) present in THL can significantly and specifically inhibit VEGF induced angiogenesis by suppressing VEGF receptor-2 (VEGFR-2) phosphorylation. These results are of clinical significance as these inexpensive and non-toxic natural products can be used for the prevention and treatment of diseases where VEGF induced angiogenesis has an important role.